Breathing brief, moderate bouts of low oxygen trigger (low oxygen therapy, LOT) spinal plasticity (the ability of the nervous system to strengthen neural pathways based on new experiences), and improve walking after spinal cord injury (SCI). The greatest improvements in walking ability occur when LOT is administered prior to skill-based walking practice (WALK). However, the enduring benefits of LOT on walking recovery may be undermined by the accumulation of LOT-induced increase in extracellular adenosine. The goal of the study is to understand the extent to which istradefylline (adenosine 2a receptor antagonist) may limit the competing mechanisms of adenosine on LOT-induced walking recovery following SCI.

开始日期2027-09-01

申办/合作机构

The Spaulding Rehabilitation Hospital Corp.

NCT07704385

/ Not yet recruiting临床1/2期IIT

Enhancing Rehabilitation in Aging Study (ERAS)

Acute Intermittent Hypoxia (AIH) is a rehab approach attributed to serotonin. AIH signaling also occurs via adenosine, and the pathways inhibit each other. Increased neural adenosine in aging may stymie AIH plasticity. The hypothesis is pre-treatment with adenosine 2A receptor inhibition (A2AI) enhances AIH effects on motor plasticity in unaffected adults. AIH exposures will be paired with A2AI or placebo, with a 4-week washout. Primary outcome measures include inspiratory and grip strength.

开始日期2026-10-01

申办/合作机构

University of Florida

JPRN-jRCTs051250026

/ Recruiting临床2期

Clinical trial on the efficacy and safety of istradefylline as an adjunctive therapy for obsessive-compulsive disorder

开始日期2025-05-19

申办/合作机构-

100 项与伊曲茶碱相关的临床结果

登录后查看更多信息

100 项与伊曲茶碱相关的转化医学

登录后查看更多信息

100 项与伊曲茶碱相关的专利（医药）

登录后查看更多信息

422

项与伊曲茶碱相关的文献（医药）

2026-10-01·NEUROPHARMACOLOGY

The adenosine A2A receptor antagonist KW6002 mitigates aldosterone-induced central serous chorioretinopathy in mice

Article

作者: Yang, Jiasheng ; Xu, Kailang ; Tang, Wei-Hang ; Liu, Qiaoli ; Yu, Zijun ; Li, Jiaqi ; Chen, Jiang-Fan ; Qu, Jia ; Que, Jia-Nan

PURPOSE:

Central serous chorioretinopathy (CSC), a prevalent disease characterized by choroidal vascular abnormalities, has extremely limited treatment options. This study investigates the effects of the selective adenosine A_2A receptor (A_2AR) antagonist KW6002 on choroidal vascular hyperpermeability and the blood-retinal barrier (BRB), and explores its therapeutic potential in experimental CSC.

METHODS:

We examined A_2AR expression in the retinal pigment epithelium (RPE)-choroid-sclera complex using quantitative real-time PCR (qPCR) and Western blotting (WB) in mice with an established aldosterone-induced acute CSC model. Before modeling and after model establishment, mice were administered 5 mg/kg KW6002 or a vehicle control via intraperitoneal injection. The retinal and choroidal thickness was assessed by optical coherence tomography (OCT) and hematoxylin-eosin (H&E) staining. We observed Müller cells activation, retinal microglia infiltration, and proinflammatory cytokine expression via immunofluorescence and qPCR. Next, we employed the effects of the A_2AR antagonist KW6002 and genetic A_2AR knockout (A_2AR-KO) on BRB integrity using immunofluorescence and WB. Finally, to clarify how A_2AR knockout confers therapeutic benefits in CSC, we assessed activation of the TNF-α/NF-κB-MMP-2/9 signaling pathway.

RESULTS:

We found that A_2AR signaling was significantly upregulated in the RPE-choroid-sclera complex in CSC models, and both A_2AR antagonist KW6002 and A_2AR-KO significantly inhibited the aldosterone-induced central retinal and choroidal pathologic thickening. Moreover, the KW6002 intervention decreased the activation of Müller cells and the proliferation of microglia, inhibited the secretion of proinflammatory cytokines (TNF-α, IL-6, and IL-1β), and ameliorated the retinal damage caused by aldosterone; in contrast, A_2AR-KO resulted in significant upregulation of key tight junction proteins (ZO-1, Claudin-1, and Claudin-5). In summary, these results suggest that the protective effects may be correlated with the suppression of the TNF-α/NF-κB-MMP-2/9 signaling axis.

CONCLUSIONS:

Our findings show that the A_2AR antagonist KW6002 or A_2AR-KO offers a protective effect in experimental CSC, reduces inflammation, and maintains the integrity of the BRB, which may be associated with the inhibition of the TNF-α/NF-κB-MMP-2/9 pathway. These findings present a new method for preventing and treating CSC, which will guide our future clinical strategy development.

2026-06-01·Purinergic Signalling

Purinergic modulation in Parkinson’s disease: the dual role of istradefylline in motor and cognitive outcomes

Review

作者: Rejili, Mokhtar ; Shokr, Mustafa M ; Al-Gareeb, Ali I ; Al-Kuraishy, Hayder M ; Jabir, Majid S ; Albuhadily, Ali K ; Batiha, Gaber El-Saber

Istradefylline, a selective adenosine 2A receptor (A2AR) antagonist, was approved in 2019 as an adjuvant treatment to reduce "OFF" periods in Parkinson's disease (PD) patients. This comprehensive review evaluates its dual impact on PD, contrasting established therapeutic benefits in motor symptom management with emerging concerns regarding cognitive safety. Istradefylline enhances dopaminergic transmission in the substantia nigra pars compacta (SNpc), significantly reducing L-DOPA-induced akinesia. Beyond motor control, it exhibits neuroprotective potential by mitigating neuroinflammation, oxidative stress, and alpha-synuclein-induced neurotoxicity. However, preclinical evidence suggests a concerning paradox: istradefylline may exacerbate cognitive decline by promoting amyloid-beta (Aβ) accumulation through the overactivity of γ-secretase and the disruption of brain-derived neurotrophic factor (BDNF) signaling pathways. Furthermore, its inhibitory effect on D-aspartate protein may trigger mitochondrial dysfunction and endoplasmic reticulum stress, potentially accelerating neurodegeneration in the SNpc. While istradefylline remains a valuable non-dopaminergic strategy for stabilizing motor fluctuations, its influence on long-term cognitive function necessitates careful clinical consideration. Understanding the molecular mechanisms behind these opposing effects is essential for optimizing its use and minimizing neurocognitive risks in PD patients. Future longitudinal trials are vital to clarify its long-term safety profile and disease-modifying potential.

2026-06-01·TISSUE & CELL

Adenosine A₂A receptor as a dual-acting molecular switch: Glial morphological changes and neurovascular tissue remodeling in neuroinflammation and neurodegeneration

Review

作者: Khalifa, Heba S ; Ali, Mohamed A M ; Elnaghy, Fatma ; El-Moaty, Heba Ibrahim Abd ; Sameh, Ahmed ; Elmorsy, Elsayed A ; Ibrahim, Essam H ; Hasan, Waseem Ali ; Hamad, Rabab S ; Morsy, Kareem ; AlShehri, Mohammed A ; El-Kott, Attalla F ; Gaafar, Ahmed ; Saber, Sameh ; Farrag, Alshaimaa A ; Alsoqih, Norah Suliman ; Negm, Sally ; Eissa, Hanan

Neuroinflammation appears in a variety of neurological disorders, including multiple sclerosis (MS), Parkinson's disease (PD), Alzheimer's disease (AD), and amyotrophic lateral sclerosis. The adenosine A₂A receptor (A₂AR), a Gs protein-coupled receptor that affects cAMP signaling and downstream kinases like PKA, CREB, and NF-κB, is one of the primary regulators of this process. Context-dependent effects of A₂AR activation include lowering acute inflammation and promoting neuronal survival when stimulated moderately, but increasing glial activation and cytokine production when overexpressed over an extended period of time. In microglia and astrocytes, A₂AR signaling regulates inflammatory pathways mediated by NF-κB and MAPK, affecting oxidative stress, blood-brain barrier (BBB) stability, and excitotoxicity. Acute or transient (short-term) A₂AR activation, on the other hand, increases the production of anti-inflammatory cytokines like IL-10 and enhances neurotrophic support through BDNF. A₂AR antagonists, including istradefylline and SCH58261, may reduce microglial triggering and have neuroprotective benefits, according to clinical and experimental data. The context-dependent activity of the receptor is shown by the fact that total receptor blockage interferes with adaptive immune control. Therefore, the therapeutic challenge is to carefully modify A₂AR signaling in particular cell populations, specifically targeting astrocytic or microglial receptors while maintaining the peripheral immunoregulatory activities. The dual regulatory role of A₂AR in neuroinflammation is summarized in this review along with its molecular mechanisms, disease-specific actions, and therapeutic significance. Developing next-generation neuroprotective strategies that reduce A₂AR signaling's pro-inflammatory and neurotoxic effects while preserving its beneficial homeostatic effects will require an understanding of the temporal and cell-specific dynamics of this signaling.

项与伊曲茶碱相关的新闻（医药）

2026-09-07

·药事纵横

针对创新药油腻病的望闻问切

面对越来越难溶的分子，制药行业并非无所作为。过去三十年间，围绕什么样的分子能成药这一问题，理论框架经历了一场从粗放到精细、从一刀切到分层化、从经验规则到机制理解的演进。这条演进线的起点，是一个边界值均为5的整数倍的简单过滤器；终点，是一套能够根据分子理化数据计算出所需粒径、以实现充分吸收的工程化体系。回望这一过程，可以清晰地看到行业学会学习的轨迹。一、Lipinski到底说了什么以及他没说什么 1997年，Lipinski、Lombardo、Dominy 和 Feeney 在 Advanced Drug Delivery Reviews 上发表了一篇后来被引用数万次的文章。五规则的诞生背景相当务实：辉瑞内部正被高通量筛选（HTS）产生的大量能结合靶标但完全不像药的分子淹没，急需一个简洁有效的过滤器来减少下游浪费。四条规则，即分子量不超过500 Da、logP不超过5、氢键供体不超过5、氢键受体不超过10，这是基于2245个进入II期临床的化合物的回顾性统计。它并非基于第一性原理推导，而是一项基于数据的回顾性总结。正因为它是统计结果而非理论推演，其说服力反而更强：绝大多数口服吸收药物确实落在这个范围内。但此处有一个关键细节，后来的引用者常忽略。Lipinski 本人从未断言遵守五规则即为好药，违反即为坏药。他反复强调的是：违反两条以上，意味着口服吸收风险升高——这属于预警信号，而非否决票。它提示团队应在更早阶段评估吸收性质，而非留到临床前才处理。这与后来许多公司将之作为硬性门槛的做法，相去甚远。 Walters 在2012年回顾Ro5发表十五年影响时，写下了一句意味深长的评论：Lipinski的规则让药物化学家对理化性质与ADMET之间的关系有了更多意识，但它远非万能药。他指出了一个根本问题：Ro5描述的是过去成功药物的特征，却无法预测对于一个全新的、前所未有的靶标，未来的成功药物应具何种特征。更危险的是，Ro5容易制造一种虚假安全感：一个分子若四条皆符，团队便觉得没问题了，而事实是，四条皆符但溶解度极差的分子比比皆是。Ro5并未要求测定溶解度，它给出的仅是一个概率判断。二、规则的繁衍以及繁衍的代价 Ro5之后，规则开始成倍增长。Veber在2002年补充了两个参数：可旋转键不超过10个，极性表面积（TPSA）不超过140 Å²。其数据显示，这两个参数与口服生物利用度的相关性甚至优于Ro5。Ghose及同事提出了一套更精细的数值范围；Oprea则区分了类药（drug-like）与类先导（lead-like）两个不同化学空间——先导化合物应比药物更小、更亲水、更简单，因为先导优化本身是一条只能增不能减的单行道。若从一个450 Da的先导出发，待优化完毕，它可能已变成550 Da的候选分子，从Ro5的内侧滑到了外侧。Oprea的逻辑是：先导应从严要求，预留出增重空间。此外，还涌现出各种多参数过滤器：REOS、PAINS（用于排除在生化实验中产生假阳性信号的泛反应干扰物）、以及各类QSPR模型。到2018年Mignani等人撰写综述时，已累积了足够多的过滤器，可填满整张表格。该文提出了一个尖锐问题：这些规则能否进一步简化？答案是否定的：分子复杂性不允许简单的二元判断。所需并非一个更优的过滤器，而是一套分层化、情境化的评估体系。这也是为何bRo5（beyond Rule of Five）概念的提出，在认识论上构成一个重要转折。Doak等人在2014年指出：自然界中大量存在违反Ro5却仍能口服吸收的分子。环孢素A一个含11个氨基酸的环肽，分子量1202 Da，logP > 14，堪称最极端的例证。其核心在于一种构象变色龙行为：穿越脂质膜时形成分子内氢键，掩蔽极性基团，暴露疏水表面；进入水相后则反向切换。这种动态策略，恰好调和了透膜性与溶解性之间的静态矛盾。 bRo5并未被设计为一套新规则，它更像是一种视角转换。不再问这个分子违规了，行不行？而是问这个分子属于bRo5范畴，其构象行为如何？分子内氢键网络是否具有可利用的动态性？这一转换，使问题从是否可行转向了如何实现。三、rDCS：从这个分子行不行到这个分子该怎么处理如果说Ro5和bRo5的核心问题是分子能否成药，那么Dressman团队在过去十几年推动的可开发性分类体系，则聚焦于一个更具体的问题：该分子若欲成药，应如何制剂？ BCS是这套体系的起点。1995年Amidon等人按照高/低溶解度高/低渗透性两个维度，将药物分为四类。这一框架至今仍广泛用于FDA和EMA的审评。但BCS存在若干众所周知的不足。首先，其对高溶解度的定义：单次最高治疗剂量在250 mL水（模拟空腹胃液体积）中完全溶解，对许多现代药物而言过于宽松。那些需数十毫克乃至上百毫克才能产生药理效应的分子，在此标准下被划入BCS I类（好溶），但其在实际肠道条件下的溶解行为可能相当差。其次，BCS仅考虑平衡溶解度，未涉及溶解速率，而许多药物的吸收成败，恰恰取决于速率而非最终浓度。图1.针对特定情形选择合适目标粒度的决策轮盘。9 DCS（可开发性分类体系，2010年由Butler和Dressman提出）引入了两个关键的差异化维度：该分子的吸收限制，究竟源于溶解度不足（溶不了），还是溶解速率过慢（来不及溶）？缩小粒径是否足以解决这一问题？这两个问题直接将分类系统与制剂策略挂钩。若属溶解速率限制且减小粒径有效，则微粉化或纳米晶可能足矣；若属根本性溶解度限制，则需无定形固体分散体（ASD）或脂质制剂等重武器介入。 rDCS（精炼DCS）是Dressman团队在2023至2024年间发表的三篇系列工作的成果，代表了这一思路的最新进展。rDCS的巧妙之处在于：它无需开展新实验，仅凭已有的理化数据，如溶解度与渗透性数值、pKa、pKb，即可计算出为实现充分吸收，该药物需达到的粒径。它还将过饱和与沉淀行为分层纳入分类框架：对于弱碱药物，从胃到小肠的pH跃升可能产生过饱和，但该过饱和能维持多久？是否会在吸收前即发生沉淀？rDCS依据体外的过饱和/沉淀实验，为这些分子分配风险等级。一项颇具说服力的验证来自六个真实原料药的对比分析：伏立康唑（voriconazole）和伊曲茶碱（istradefylline）在传统BCS下均属II类，但在rDCS框架下，伏立康唑被重新划入I类，无需特殊增溶制剂，常规片剂即可；而伊曲茶碱则被确认属IIb类，需要切实的溶解度增强策略。若团队在项目早期即获此信息，可能意味着节省数月开发时间和数百万美元成本。四、框架之外：我们还缺什么？将Ro5、bRo5和rDCS串联起来，可见一条清晰的认知轨迹：从大概率可行到何时可能不行，再到若可能不行，应精确如何处置。这是可观的进步。然而在这些框架之外，仍有几个问题悬而未决。其一，所有分类与预测均高度依赖高质量的溶解度数据。但多数药企内部的溶解度实测数据——尤其是热力学溶解度，而非DMSO母液的动力学溶解度——仍然不完整、不统一、不可靠。这好比拥有精密的导航系统，却输入了一张存在大量空白的底图。其二，包括rDCS在内的所有分类，目前仍基于稳态体外测量。当ASD和脂质制剂已将过饱和这种高度动态的行为变为常态后，针对这类非稳态体系的体外到体内转化（IVIVC），仍是一个尚未闭合的缺口。体外的沉淀与体内的沉淀，可能发生在截然不同的条件下，遵循截然不同的动力学。其三，也是最棘手的问题：分类与预测框架日趋完善，但它们擅长诊断，却无法预防。药物化学家拿到rDCS结果后，知道了自己的分子需要某种高难度制剂，但这一信息本身并不能帮助他反向修改分子结构以改善可开发性。这正是第五章所要讨论的内容——当诊断已经足够好时，补救策略能否同步跟进。参考文献 1.Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification.Pharmaceutical Research, 1995, 12(3): 413-420. 2.Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.Advanced Drug Delivery Reviews, 1997, 23(1-3): 3-25. 3.Walters WP. Going further than Lipinski's rule in drug design.Expert Opinion on Drug Discovery, 2012, 7(2): 99-107. 4.Veber DF, Johnson SR, Cheng HY, et al. Molecular properties that influence the oral bioavailability of drug candidates.Journal of Medicinal Chemistry, 2002, 45(12): 2615-2623. 5.Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery.Journal of Combinatorial Chemistry, 1999, 1(1): 55-68. 6.Oprea TI, Davis AM, Teague SJ, Leeson PD. Is there a difference between leads and drugs?Journal of Chemical Information and Computer Sciences, 2001, 41(5): 1308-1315. 7.Mignani S, Rodrigues J, Tomas H, et al. Present drug-likeness filters in medicinal chemistry during the hit and lead optimization process: how far can they be simplified?Drug Discovery Today, 2018, 23(3): 605-618. 8.Doak BC, Over B, Giordanetto F, Kihlberg J. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates.Chemistry & Biology, 2014, 21(9): 1115-1142. 9.Beran K, Hermans E, Holm R, Sepassi K, Dressman J. Projection of target drug particle size in oral formulations using the refined Developability Classification System (rDCS).Pharmaceutics, 2023, 15(7): 1909. 10.Beran K, Hermans E, Holm R, Sepassi K, Dressman J. Using the refined Developability Classification System (rDCS) to guide the design of oral formulations.Journal of Pharmaceutical Sciences, 2024, 113(4): 1210-1221. 11.Beran K, Hermans E, Holm R, Sepassi K, Dressman J. A stratified analysis of supersaturation and precipitation effects based on the refined Developability Classification System (rDCS).Journal of Pharmaceutical Sciences, 2024, 113(7): 1816-1827. 立即扫码加入药事纵横交流群

2026-09-02

·BioSpace

Marvel Biosciences Announces Grant of Deferred Share Units

Calgary, Alberta--(News - September 1, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), announces the award of 50,001 deferred share units (" DSUs ") to Marvel's three independent directors, in lieu of cash payment for directors' fees. The DSUs will all vest on September 1, 2027. Vested DSUs shall be settled upon the directors' separation from service from the Company and expire 365 days after such directors' separation from service. The deemed value for the DSUs is calculated using the VWAP of the Corporation's Common Shares on the TSX Venture Exchange on August 31, 2026 being $0.15 multiplied by the number of DSUs awarded. About Marvel Biosciences Corp. Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary- based pre-clinical stage pharmaceutical development biotechnology company. The Company is developing MB-204, a novel ﬂuorinated derivative of the approved anti-Parkinson's drug Istradefylline, the only clinically approved adenosine A2a antagonist. A signiﬁcant and growing body of scientiﬁc evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer's Disease. The Company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett Syndrome and Fragile X Syndrome, to expand its therapeutic reach. Contact Information: Marvel Biosciences Corp. J. Roderick (Rod) Matheson, Chief Executive Officer or Dr. Mark Williams, President and Chief Science Officer Tel: 403 770 2469 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is deﬁned in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and oﬃcers have relied on each other for any information concerning such Party. This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identiﬁed by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could diﬀer materially from those anticipated in such statements. Important factors that could cause actual results to diﬀer materially from the expectations of the Company and include other risks detailed from time to time in the ﬁlings made by the Company under securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to diﬀer materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may diﬀer materially from those anticipated. Forward-looking statements contained in this news release are expressly qualiﬁed by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law. To view the source version of this press release, please visit

上市批准

2026-09-01

·Biotech前瞻

百济只是其中之一：特朗普MFN再扩围，9家药企谁受影响最大？

特朗普政府的药价谈判，开始从大型跨国药企向中型制药企业延伸。当地时间8月31日，白宫宣布与爱尔康、安斯泰来、百济神州、BridgeBio、CSL、协和麒麟、太阳制药、梯瓦和优时比等9家药企达成最惠国药价协议。至此，与美国政府达成MFN安排的药企增至26家，覆盖美国约89%的品牌药市场。九家公司还承诺，近期在美国投入至少196亿美元用于制造业建设。国内市场的注意力主要集中在百济神州及替雷利珠单抗，但从产品规模看，百济并不是这批企业中潜在影响最大的一家。九家公司背后涉及前列腺癌、血友病、罕见病、自身免疫病、神经系统疾病和眼科疾病等多个高价值市场，其中不乏年销售额数十亿美元的重磅产品。不只是替雷利珠单抗根据目前披露的信息，百济神州将通过Medicaid项目，以约定价格向符合条件的患者提供替雷利珠单抗。替雷利珠单抗已经在全球50多个市场获批。2026年第二季度，其全球销售额约为2.29亿美元，按单季简单年化接近9亿美元。协议预计覆盖的患者约占替雷利珠单抗美国已获批适应证患者群体的8%，因此短期财务影响可能相对有限。百济神州在美国规模更大的产品是BTK抑制剂泽布替尼。2026年第二季度，泽布替尼全球销售额约12.5亿美元，其中美国市场约8.93亿美元。但截至目前，没有公开信息显示泽布替尼被明确纳入本次具体定价安排。相比之下，其余八家药企中，多家公司拥有规模更大的成熟产品。需要注意的是，白宫只公布了血友病、帕金森病、黄斑变性、青光眼、肝病、皮肤病和癌症等疾病类别，没有披露九家公司逐一对应的药品清单及折扣幅度。因此，上表列出的是相关企业在美国最主要、与白宫所述疾病较为匹配的产品，不代表这些药品已经全部确认降价。安斯泰来和UCB的产品规模更大安斯泰来从现有产品规模看，安斯泰来是这批企业中值得重点关注的一家。其核心产品XTANDI用于前列腺癌，2025财年销售额达到9608亿日元，是全球规模最大的肿瘤药物之一。ADC产品PADCEV同期销售约2212亿日元，地图样萎缩药物IZERVAY销售约776亿日元，CLDN18.2抗体VYLOY销售约631亿日元。白宫公告同时提到癌症和黄斑变性，与安斯泰来的肿瘤及眼科产品组合高度重合。但公司没有公布哪些药物将进入MFN框架，也没有披露价格调整幅度。优时比 UCB的潜在影响同样不容忽视。2026年上半年，IL-17A/F抗体BIMZELX实现销售15.28亿欧元，同比增长91%。优时比已将其峰值销售预期上调至至少70亿欧元。该药在美国覆盖银屑病、银屑病关节炎、强直性脊柱炎和化脓性汗腺炎等多个适应证，是目前增长最快的自身免疫药物之一。同期，CIMZIA销售9.54亿欧元，罕见癫痫药FINTEPLA销售2.39亿欧元，重症肌无力药物RYSTIGGO和ZILBRYSQ分别销售1.92亿和1.39亿欧元。对于优时比而言，短期影响取决于Medicaid患者占比；长期影响则在于，BIMZELX后续适应证和新产品的美国价格可能需要与其他发达国家进一步联动。罕见病企业也被纳入谈判 BridgeBio是目前披露最为明确的一家公司。其确认将ATTR-CM药物Attruby纳入GENEROUS模式，以扩大Medicaid患者的用药可及性。2026年第二季度，Attruby美国净销售额达到2.224亿美元，按单季度简单年化已经接近9亿美元。BridgeBio同时强调，Attruby在Medicare Part D渠道的销售不会受到本次协议直接影响，公司原有患者援助计划也将继续执行。CSL的产品规模更大。其CSL Behring板块2026财年收入达到113.87亿美元，拥有免疫球蛋白、凝血因子、遗传性血管性水肿药物以及血友病B基因疗法HEMGENIX。白宫公告明确提到血友病，但CSL没有公布具体涉及IDELVION、AFSTYLA还是HEMGENIX。公司预计协议不会对2027财年产生重大影响，显示现阶段的价格让步可能主要集中在患者规模较小的Medicaid渠道。协和麒麟则拥有CRYSVITA、POTELIGEO和NOURIANZ三款主要产品。其中，CRYSVITA用于X连锁低磷血症等罕见疾病，2026年收入指引达到2354亿日元；POTELIGEO用于皮肤T细胞淋巴瘤，全年收入指引546亿日元；NOURIANZ是帕金森病辅助治疗药物，全年收入指引74亿日元。白宫特别提到帕金森病，NOURIANZ因而成为最容易被联想到的产品，但协和麒麟只表示“部分药品”参与，并未确认具体品牌。太阳制药、梯瓦和爱尔康分别对应哪些市场？太阳制药在美国的创新药业务主要集中于皮肤科和皮肤肿瘤。其产品包括银屑病药物ILUMYA、斑秃药物LEQSELVI、晚期皮肤鳞癌药物UNLOXCYT、基底细胞癌药物ODOMZO以及痤疮药物WINLEVI。2027财年第一季度，太阳制药全球创新药销售额约3.51亿美元，占公司收入的21.9%，按单季年化约14亿美元。白宫所提到的皮肤病和癌症，与该公司产品结构基本对应。梯瓦的核心创新药包括运动障碍药物AUSTEDO、偏头痛药物AJOVY和精神分裂症长效针剂UZEDY。2026年第二季度，三款产品分别实现销售6.96亿、2.44亿和7700万美元，公司预计全年合计收入约37亿美元。不过，梯瓦与另外八家公司存在一个差异：白宫将其列入已签约名单，但梯瓦自身公告使用的是“拟达成协议”，并称双方仍在谈判。因此，梯瓦协议现阶段更接近原则性共识，最终条款尚待确认。爱尔康则主要对应青光眼市场。其处方药包括ROCKLATAN、RHOPRESSA和SIMBRINZA。2025年，公司Ocular Health业务收入约17.98亿美元，但这一数据还包含干眼及消费者眼健康产品。爱尔康规模更大的人工晶体、眼科手术设备和隐形眼镜业务不属于Medicaid处方药定价范围，本次协议的实际影响应主要集中在眼科处方药板块。不是全面下调美国药价 MFN协议并不意味着九家公司会在美国全面降低药品目录价。按照CMS公布的GENEROUS模式，参与企业主要通过向州Medicaid项目提供补充返利，使药品净支付价格接近选定发达国家的价格水平。各州可以自主决定是否参与，以及选择哪些药品执行MFN价格。2024年，美国Medicaid处方药净支出约600亿美元，较2022年增加100亿美元。企业接受更低净价后，可以换取相对统一的覆盖标准，并减少与各州分别谈判补充返利的成本。这意味着，短期影响主要取决于三项因素：具体纳入哪些药品、Medicaid患者占比，以及降价后能否换来更宽松的准入和更高的用药量。对替雷利珠单抗、Attruby等Medicaid患者比例有限的产品而言，降价未必明显影响整体收入；如果覆盖改善带来患者增量，部分价格损失还可能被销量抵消。更大的影响在未来产品定价相比现有药品的Medicaid返利，协议中有关未来创新药的约束更值得关注。九家公司承诺，未来在美国上市的创新药将提供与其他发达国家相衔接的价格。美国市场长期承担着全球创新药的大部分利润，一旦美国价格与欧洲、加拿大或日本的低价形成联动，药企可能重新安排全球上市顺序。价格较低的国家可能被推迟上市，海外净价谈判也可能趋于强硬。部分企业还可能减少公开折扣，更多使用保密返利，避免某一市场的低价成为美国定价参照。与此同时，这项协议也并非单向降价。九家公司合计承诺至少196亿美元的美国制造业投资，部分企业还将向美国战略原料药储备捐赠抗生素、抗癫痫药和免疫抑制剂原料。部分公司则获得关税豁免、延期或更明确的政策预期。从交易结构看，这是一项由药价、市场准入、关税和本土制造共同组成的政策交换。百济神州因替雷利珠单抗受到国内关注，但从产品规模看，安斯泰来、CSL、UCB和梯瓦的潜在暴露更大；从长期影响看，受到冲击的也不只是九家公司当前的销售收入，而是创新药在美国定高价、再向全球扩散的传统商业模式。

100 项与伊曲茶碱相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04641	伊曲茶碱	N04B	DB11757

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
帕金森病	日本	Kyowa Kirin Co., Ltd.	2013-03-25

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
原发性帕金森病	临床3期	中国	石药集团中奇制药技术（石家庄）有限公司	2019-02-28
轻度认知障碍	临床2期	美国	Kyowa Kirin, Inc.	2022-07-18
不宁腿综合征	临床2期	美国	Kyowa Kirin, Inc.	2005-07-01
药物滥用	临床1期	美国	Kyowa Kirin Co., Ltd.	2016-01-01
恶病质	临床1期	美国	Piston Bio LLC	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


MDS2024	N/A	帕金森病	2,045	Istradefylline 40 mg	壓鹹衊製鹽蓋膚鹹觸願(繭選選觸選顧衊襯蓋壓) = 網衊繭淵鏇廠艱窪齋襯鏇淵範襯築顧窪鑰衊艱 (鑰範遞鑰蓋膚鬱觸襯醖, 90 ~ 365) 更多	积极	2024-09-27
				Istradefylline 40 mg (Medicare replacement)	壓鹹衊製鹽蓋膚鹹觸願(繭選選觸選顧衊襯蓋壓) = 衊選鬱艱觸積廠衊鬱蓋鏇淵範襯築顧窪鑰衊艱 (鑰範遞鑰蓋膚鬱觸襯醖, 90 ~ 365) 更多
P5-3.017 (AAN2024)	N/A	帕金森病	-	Istradefylline 40mg	觸願糧積網觸積餘選願(築鬱繭餘鏇窪艱簾遞艱) = The odds of hallucinations were significantly higher for amantadine vs. istradefylline at 40 and 20mg 繭觸艱鹹鏇衊鏇窪獵襯 (構鏇鏇製製鬱鑰夢艱鑰 ) 更多	积极	2024-04-09
				Istradefylline 20mg
MDS2023	临床3期	-	214	Istradefylline	醖獵鑰網顧齋鑰獵鏇夢(選獵膚遞選衊夢選簾遞) = 鬱簾觸選壓簾襯襯壓壓齋襯廠窪簾壓夢構遞淵 (築鑰鑰衊願製壓廠鹽願 )	积极	2023-08-27
				No Istradefylline	醖獵鑰網顧齋鑰獵鏇夢(選獵膚遞選衊夢選簾遞) = 衊衊艱選襯艱壓鹽憲選齋襯廠窪簾壓夢構遞淵 (築鑰鑰衊願製壓廠鹽願 )
AAN2022	N/A	帕金森病	-	Istradefylline 20 mg	襯膚衊糧餘遞簾製繭顧(餘蓋艱繭夢遞製築製繭) = 夢製鬱鑰淵艱廠夢鹽壓艱夢衊鏇鏇衊繭淵顧築 (襯鬱餘襯遞網窪鬱鏇鑰 ) 更多	积极	2022-05-03
				Istradefylline 40 mg	醖觸醖餘顧夢襯簾遞顧(顧餘鹹夢築獵鹹繭襯選) = 糧醖糧構遞廠獵夢繭遞蓋範選顧衊獵鹽鑰鬱遞 (鏇廠積蓋齋製鹹築顧製 )
NCT01968031 (KW-6002, CTgov)	临床3期	帕金森病	613	Placebo (Placebo)	鬱願鏇窪齋廠鬱壓願膚(夢簾糧壓願衊獵齋餘蓋) = 築夢襯夢製夢積衊構顧鏇廠網鬱範鬱鹹膚憲憲 (鏇壓顧顧製簾鹽鏇願顧, 遞蓋築窪製製遞壓艱構 ~ 壓願憲鬱廠鏇築衊製夢) 更多	-	2020-11-20
				Placebo+Istradefylline 20 mg (Istradefylline 20 mg/Day)	鬱願鏇窪齋廠鬱壓願膚(夢簾糧壓願衊獵齋餘蓋) = 醖壓顧艱襯鑰窪餘網窪鏇廠網鬱範鬱鹹膚憲憲 (鏇壓顧顧製簾鹽鏇願顧, 糧齋構鑰糧夢艱構積膚 ~ 衊範壓鑰鑰鬱餘範製積) 更多
pooled analysis of four pivotal randomized controlled trials of istradefylline (ANA2020)	临床3期	帕金森病	1,143	Istradefylline 20mg/day	膚積餘蓋窪範範窪築糧(積鏇窪糧顧齋齋淵憲蓋) = 製築鏇觸製艱製壓醖網襯製艱築蓋鹹鹽願繭鹽 (齋選繭餘範艱蓋蓋願構, -1.10 ~ -0.40) 更多	积极	2020-09-25
				Istradefylline 40mg/day	膚積餘蓋窪範範窪築糧(積鏇窪糧顧齋齋淵憲蓋) = 獵膚選衊糧獵願簾淵網襯製艱築蓋鹹鹽願繭鹽 (齋選繭餘範艱蓋蓋願構, -1.17 ~ -0.47) 更多
ANA2020	临床2/3期	-	1,160	Istradefylline 20 mg/day	製艱壓憲製鑰願積築憲(築願選蓋艱觸鬱夢顧製) = The most common TEAE was dyskinesia (20 mg/day, 14.6%; 40 mg/day, 16.7%; placebo, 7.5%) 淵餘淵壓鬱醖選範蓋廠 (鑰窪遞鹽鬱蓋醖鹽鬱網 ) 更多	积极	2020-09-25
				Istradefylline 40 mg/day
MDS2020	N/A	-	31	Istradefylline 20 mg/day	壓鹽憲襯繭廠構壓製窪(鹹廠蓋選餘餘顧願積壓) = 2 (6.5%) patients 鹹鏇醖簾網餘膚襯淵憲 (獵顧夢廠齋願淵範網鏇 ) 更多	-	2020-09-12
				Placebo
MDS2020	临床2/3期	帕金森病	1,143	Istradefylline 20mg/day	築鹽膚襯願鹽選遞構鹽(齋構選壓範夢願顧鏇築) = Dyskinesia was the most frequent adverse event (20mg, 15%; 40mg, 17%; placebo, 8%) 壓鬱憲鹹齋膚顧積襯鏇 (顧醖鏇範範淵衊觸鑰遞 )	积极	2020-09-12
EAN2020	N/A	帕金森病	-	Istradefylline 40mg/day	鑰顧獵顧觸製醖醖鏇鏇(積壓餘廠膚淵艱觸簾遞) = Among TEAEs (frequency â¥5%), nasopharyngitis, dyskinesia, contusion, and constipation became more frequent with dose increase vs maintaining 20mg/day 構夢夢築齋鹽築憲襯憲 (網觸網衊築糧襯鑰積製 )	-	2020-05-22
				Placebo